Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability

References

• ShawJESicreeRAZimmetPZGlobal estimates of the prevalence of diabetes for 2010 and 2030Diabetes Res Clin Pract201087141419896746
   PubMed Web of Science ®Google Scholar
• HolzGG4thKühtreiberWMHabenerJFPancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7–37)Nature199336164103623658381211
   PubMed Web of Science ®Google Scholar
• FreemanJSThe pathophysiologic role of incretinsJ Am Osteopath Assoc2007107SupplS6S917724014
   PubMedGoogle Scholar
• NauckMABallerBMeierJJGastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetesDiabetes200453Suppl 3S190S19615561910
   PubMed Web of Science ®Google Scholar
• AhrénBFoleyJEThe islet enhancer vildagliptin: mechanisms of improved glucose metabolismInt J Clin Pract Suppl200815981418269436
   PubMedGoogle Scholar
• BanerjeeMYounisNSoranHVildagliptin in clinical practice: a review of literatureExpert Opin Pharmacother200910162745275719874253
   PubMed Web of Science ®Google Scholar
• PalalauAITahraniAAPiyaMKBarnettAHDPP-4 inhibitors in clinical practicePostgrad Med200912167010019940419
   PubMed Web of Science ®Google Scholar
• ThornberryNAGallwitzBMechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)Best Pract Res Clin Endocrinol Metab200923447948619748065
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBDiamantMfor American Diabetes Association (ADA)European Association for the Study of Diabetes (EASD)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• KeatingGMVildagliptin: a review of its use in type 2 diabetes mellitusDrugs201070162089211220964454
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilHAAssociation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ2000321725840541210938048
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS)VIII. Study design, progress and performanceDiabetologia199134128778901778353
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2011Diabetes Care201134Suppl 1S11S6121193625
   PubMed Web of Science ®Google Scholar
• BennettWLMaruthurNMSinghSComparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsAnn Intern Med2011154960261321403054
   PubMed Web of Science ®Google Scholar
• JiLLJWengJChina Type 2 Diabetes Treatment Status Survey of Treatment Pattern of Oral Drugs Users (China DiaSTAGE)BerlinThe 48th European Association for the Study of Diabetes2012
   Google Scholar
• PetersAIncretin-based therapies: review of current clinical trial dataAm J Med2010123Suppl 3S28S3720206729
   PubMed Web of Science ®Google Scholar
• ArodaVRHenryRRHanJHuangWEfficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic ReviewClin Ther201263461247125822608780
   PubMed Web of Science ®Google Scholar
• DejagerSRazacSFoleyJESchweizerAVildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose studyHorm Metab Res200739321822317373638
   PubMed Web of Science ®Google Scholar
• ScherbaumWASchweizerAMariAEvidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemiaDiabetes Obes Metab200810111114112418355325
   PubMed Web of Science ®Google Scholar
• ScherbaumWASchweizerAMariAEfficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*Diabetes Obes Metab200810867568218248490
   PubMed Web of Science ®Google Scholar
• FoleyJEBunckMCMöller-GoedeDLBeta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trialDiabetologia20115481985199121547496
   PubMed Web of Science ®Google Scholar
• Pi-SunyerFXSchweizerAMillsDDejagerSEfficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetesDiabetes Res Clin Pract200776113213817223217
   PubMed Web of Science ®Google Scholar
• AhrénBLandin-OlssonMJanssonPASvenssonMHolmesDSchweizerAInhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetesJ Clin Endocrinol Metab20048952078208415126524
   PubMed Web of Science ®Google Scholar
• AhrénBSchweizerADejagerSVildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetesJ Clin Endocrinol Metab20099441236124319174497
   PubMed Web of Science ®Google Scholar
• FoleyJESreenanSEfficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetesHorm Metab Res2009411290590919705345
   PubMed Web of Science ®Google Scholar
• PanCYangWBaronaJPComparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trialDiabet Med200825443544118341596
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMADejagerSMillsDSchweizerAComparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabetes Care200730221722317259484
   PubMed Web of Science ®Google Scholar
• SchweizerACouturierAFoleyJEDejagerSComparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetesDiabet Med200724995596117509069
   PubMed Web of Science ®Google Scholar
• PratleyRERosenstockJPi-SunyerFXManagement of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapyDiabetes Care200730123017302217878242
   PubMed Web of Science ®Google Scholar
• KirpichnikovDMcFarlaneSISowersJRMetformin: an updateAnn Intern Med20021371253312093242
   PubMed Web of Science ®Google Scholar
• MigoyaEMMJLarsonPJTanenMRSitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase43rd EASD Annual MeetingAmsterdam2007
   Google Scholar
• HinkeSAKühn-WacheKHoffmannTPedersonRAMcIntoshCHDemuthHUMetformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1Biochem Biophys Res Commun200229151302130811883961
   PubMed Web of Science ®Google Scholar
• YasudaNInoueTNagakuraTEnhanced secretion of glucagon-like peptide 1 by biguanide compoundsBiochem Biophys Res Commun2002298577978412419322
   PubMed Web of Science ®Google Scholar
• D’AlessioDADenneyAMHermillerLMTreatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetesJ Clin Endocrinol Metab2009941818818957505
   PubMed Web of Science ®Google Scholar
• DunningBELigueros-SaylanMD’AlessioDADifferential effects of DPP-4 inhibition on incretin hormone levels in drug-naïve and metformin-treated patients with type 2 diabetesDiabetologia200649S1S110
   Google Scholar
• BosiECamisascaRPColloberCRochotteEGarberAJEffects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metforminDiabetes Care200730489089517277036
   PubMed Web of Science ®Google Scholar
• KimNHSSungYAAhnWCEfficacy and safety of add-on vildagliptin to metformin in comparison to uptitrating metformin therapyDiabetes201261S1A297
   Google Scholar
• MatthewsDRDejagerSAhrenBVildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year studyDiabetes Obes Metab201012978078920649630
   PubMed Web of Science ®Google Scholar
• BolliGDottaFRochotteECohenSEEfficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week, randomized, double-blind studyDiabetes Obes Metab2008101829018034842
   PubMed Web of Science ®Google Scholar
• BolliGDottaFColinLMinicBGoodmanMComparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metforminDiabetes Obes Metab200911658959519515179
   PubMed Web of Science ®Google Scholar
• BlondeLDagogo-JackSBanerjiMAComparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial – a primary care, type 2 diabetes studyDiabetes Obes Metab2009111097898619614942
   PubMed Web of Science ®Google Scholar
• GarberAJSchweizerABaronMARochotteEDejagerSVildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyDiabetes Obes Metab20079216617417300592
   PubMed Web of Science ®Google Scholar
• GarberAJFoleyJEBanerjiMAEffects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylureaDiabetes Obes Metab200810111047105618284434
   PubMed Web of Science ®Google Scholar
• FonsecaVBaronMShaoQDejagerSSustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitusHorm Metab Res200840642743018401832
   PubMed Web of Science ®Google Scholar
• FonsecaVSchweizerAAlbrechtDBaronMAChangIDejagerSAddition of vildagliptin to insulin improves glycaemic control in type 2 diabetesDiabetologia20075061148115517387446
   PubMed Web of Science ®Google Scholar
• LukashevichVKozlovskiPFoleyJVildagliptin combined with insulin reduces HbA1c without increasing risk of hypoglycemia and weight gain in patients with type 2 diabetes mellitusProceedings from the 72nd ADA Scientific SessionsPhiladelphia, PA, USA2012
   Google Scholar
• DuttaroyAVoelkerFMerriamKThe DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal ratsEur J Pharmacol20116502–370370721070766
   PubMed Web of Science ®Google Scholar
• AkarteASSrinivasanBPGandhiSVildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-Cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetesJ Diabetes Complications201226426627422626875
   PubMed Web of Science ®Google Scholar
• SatoKNakamuraAShirakawaJImpact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat dietEndocrinology201215331093110222315446
   PubMed Web of Science ®Google Scholar
• HamamotoSKandaYShimodaMVildagliptin preserves the mass and function of pancreatic β cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetesDiabetes Obes Metab201215215316322950702
   PubMed Web of Science ®Google Scholar
• BalasBBaigMRWatsonCThe dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patientsJ Clin Endocrinol Metab20079241249125517244786
   PubMed Web of Science ®Google Scholar
• PratleyRESchweizerARosenstockJRobust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy databaseDiabetes Obes Metab2008101093193818093207
   PubMed Web of Science ®Google Scholar
• AhrénBPaciniGFoleyJESchweizerAImproved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 yearDiabetes Care20052881936194016043735
   PubMed Web of Science ®Google Scholar
• BosiEDottaFJiaYGoodmanMVildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitusDiabetes Obes Metab200911550651519320662
   PubMed Web of Science ®Google Scholar
• UtzschneiderKMTongJMontgomeryBThe dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucoseDiabetes Care200831110811317909087
   PubMed Web of Science ®Google Scholar
• RosenstockJFoleyJERendellMEffects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose toleranceDiabetes Care2008311303517947341
   PubMed Web of Science ®Google Scholar
• AvogaroAGiordaCMagginiMfor Diabetes and Informatics Study GroupAssociation of Clinical DiabetologistsIstituto Superiore di SanitàIncidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic locationDiabetes Care20073051241124717290034
   PubMed Web of Science ®Google Scholar
• GaedePLund-AndersenHParvingHHPedersenOEffect of a multifactorial intervention on mortality in type 2 diabetesN Engl J Med2008358658059118256393
   PubMed Web of Science ®Google Scholar
• MonamiMLamannaCDesideriCMMannucciEDPP-4 inhibitors and lipids: systematic review and meta-analysisAdv Ther2012291142522215383
   PubMed Web of Science ®Google Scholar
• RosenstockJKimSWBaronMAEfficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesDiabetes Obes Metab20079217518517300593
   PubMed Web of Science ®Google Scholar
• BoschmannMEngeliSDobbersteinKDipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patientsJ Clin Endocrinol Metab200994384685219088168
   PubMed Web of Science ®Google Scholar
• AhrénBSchweizerADejagerSVillhauerEBDunningBEFoleyJEMechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humansDiabetes Obes Metab201113977578321507182
   PubMed Web of Science ®Google Scholar
• TerasakiMNagashimaMWatanabeTEffects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null miceMetabolism201261797497722225957
   PubMed Web of Science ®Google Scholar
• ChindaKPaleeSSurinkaewSPhornphutkulMChattipakornSChattipakornNCardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injuryInt J Cardiol Epub January 26, 2012.
   Google Scholar
• ApaijaiNPintanaHChattipakornSCChattipakornNCardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat dietEndocrinology201215383878388522621958
   PubMed Web of Science ®Google Scholar
• MatsuiTNishinoYTakeuchiMYamagishiSVildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axisPharmacol Res201163538338821320599
   PubMed Web of Science ®Google Scholar
• PratleyREJauffret-KamelSGalbreathEHolmesDTwelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetesHorm Metab Res200638642342816823726
   PubMed Web of Science ®Google Scholar
• KikuchiMAbeNKatoMTeraoSMimoriNTachibanaHVildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitusDiabetes Res Clin Pract200983223324019118913
   PubMed Web of Science ®Google Scholar
• MonamiMCremascoFLamannaCMarchionniNMannucciEPredictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trialsDiabetes Metab Res Rev201127436237221309062
   PubMed Web of Science ®Google Scholar
• GökeBHershonKKerrDEfficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metforminHorm Metab Res2008401289289518726829
   PubMed Web of Science ®Google Scholar
• IwamotoYKashiwagiAYamadaNEfficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled studyDiabetes Obes Metab201012870070820590747
   PubMed Web of Science ®Google Scholar
• CaiLCaiYLuZJZhangYLiuPThe efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trialsJ Clin Pharm Ther201237438639822191695
   PubMed Web of Science ®Google Scholar
• BerlieHDGarwoodCLDiabetes medications related to an increased risk of falls and fall-related morbidity in the elderlyAnn Pharmacother201044471271720215495
   PubMed Web of Science ®Google Scholar
• GersteinHCMillerMEGenuthSfor ACCORD Study GroupLong-term effects of intensive glucose lowering on cardiovascular outcomesN Engl J Med2011364981882821366473
   PubMed Web of Science ®Google Scholar
• GooßenKGräberSLonger term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysisDiabetes, Obesity and Metabolism2012141210611072
   PubMed Web of Science ®Google Scholar
• BryanJCraneAVila-CarrilesWHBabenkoAPAguilar-BryanLInsulin secretagogues, sulfonylurea receptors and K(ATP) channelsCurr Pharm Des200511212699271616101450
   PubMed Web of Science ®Google Scholar
• WardWKBeardJCHalterJBPfeiferMAPorteDJrPathophysiology of insulin secretion in non-insulin-dependent diabetes mellitusDiabetes Care1984754915026094129
   PubMed Web of Science ®Google Scholar
• TanMHBaksiAKrahulecBfor GLAL Study GroupComparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetesDiabetes Care200528354455015735185
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMAfor ADOPT Study GroupGlycemic durability of rosiglitazone, metformin, or glyburide monotherapyN Engl J Med2006355232427244317145742
   PubMed Web of Science ®Google Scholar
• ChristensenMVedtofteLHolstJJVilsbøllTKnopFKGlucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humansDiabetes201160123103310921984584
   PubMed Web of Science ®Google Scholar
• MarfellaRBarbieriMGrellaRRizzoMRNicolettiGFPaolissoGEffects of vildagliptin twice daily vs sitagliptin once daily on 24-hour acute glucose fluctuationsJ Diabetes Complications2010242798319261490
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBfor American Diabetes AssociationEuropean Association for Study of DiabetesMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care200932119320318945920
   PubMed Web of Science ®Google Scholar
• BeckerABosGde VegtFCardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn StudyEur Heart J200324151406141312909069
   PubMed Web of Science ®Google Scholar
• LeeCDFolsomARPankowJSBrancatiFLfor Atherosclerosis Risk in Communities (ARIC) Study InvestigatorsCardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarctionCirculation2004109785586014757692
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med2007356242457247117517853
   PubMed Web of Science ®Google Scholar
• KendallDMRubinCJMohideenPImprovement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative studyDiabetes Care20062951016102316644631
   PubMed Web of Science ®Google Scholar
• SchweizerADejagerSFoleyJECouturierALigueros-SaylanMKothnyWAssessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes populationDiabetes Obes Metab201012648549420518804
   PubMed Web of Science ®Google Scholar
• LukashevichVSchweizerAShaoQGroopPHKothnyWSafety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trialDiabetes Obes Metab2011131094795121733061
   PubMed Web of Science ®Google Scholar
• SchillingerDGrumbachKPietteJAssociation of health literacy with diabetes outcomesJAMA2002288447548212132978
   PubMed Web of Science ®Google Scholar